S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
CAMBRIDGE, MA—In recent transactions disclosed by Seres Therapeutics, Inc. (NASDAQ:MCRB), a $141 million market cap biotech company currently trading near its 52-week low, Lisa von Moltke, the Executive Vice President and Chief Medical (TASE:BLWV) Officer, sold shares of the company. According to a Form 4 filing with the Securities and Exchange Commission, von Moltke sold 4,416 shares on February 18, 2025, at a weighted average price of $0.8105 per share, totaling approximately $3,579.
The sales were executed under a pre-arranged Rule 10b5-1 trading plan, originally adopted on March 11, 2023. This plan was specifically designed to cover tax obligations associated with the vesting of restricted stock units.
In addition to the sales, von Moltke acquired a total of 11,876 shares of common stock on February 15, 2025, through the vesting of restricted stock units. These acquisitions were part of her compensation package and did not involve any cash transactions.
Following these transactions, von Moltke now holds 39,875 shares of Seres Therapeutics directly. The company, based in Cambridge, Massachusetts, is engaged in the development of microbiome therapeutics aimed at treating a range of diseases.
In other recent news, Seres Therapeutics has received a $50 million payment from Nestlé Health Science as part of the transition obligations following the sale of its VOWST business. This funding is expected to support Seres’ operations into the first quarter of 2026, with an additional $25 million anticipated in July 2025. In another development, the FDA has granted Breakthrough Therapy designation to Seres’ investigational drug SER-155, aimed at reducing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants. This designation follows positive Phase 1b study results showing a 77% relative risk reduction in bacterial bloodstream infections. Furthermore, Seres Therapeutics has expanded its Board of Directors by appointing Dr. Hans-Juergen Woerle as a new Class III director, a move that follows a rights agreement with Nestlé. Dr. Woerle brings extensive experience from his roles at Nestlé Health Science and other biotechnology companies. These recent developments highlight Seres Therapeutics’ ongoing efforts to strengthen its leadership and advance its pipeline of live biotherapeutic products.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.